### British Columbia (BC) COVID-19 Situation Report Week 25: June 19- June 25, 2022

# Data for week 25 (June 19 - June 25, 2022) may differ from the data published in the BCCDC weekly report. Data was extracted on July 04, 2022 for this situation report compared to July 06, 2022 for the latest weekly report.

Table of Contents	5	Report Summary					
Epidemic curve and regional incidence	<u>3</u>	Due to changes in testing strategies in BC, current case counts are an underestimate of the true number of COVID-19 cases in BC. This underestimation has increased compared to the					
Test rates and % positive	<u>4</u>	period prior to the emergence of the Omicron variant in BC. The provincial incidence by episode date was 12 per 100K (628 cases) in week 25, which is stable compared to week 24.					
Age profile, testing and cases	<u>5</u>	<ul> <li>Incidence by Health Authority from week 24 to week 25:</li> <li>Fraser Health incidence remained stable from 12 to 13 per 100K</li> <li>Interior Health incidence decreased from 11 to 9 per 100K</li> </ul>					
Severe outcomes	<u>Z</u>	• Vancouver Island Health incidence increased from 13 to 15 per 100K					
Age profile, severe outcomes	<u>9</u>	<ul> <li>Northern Health incidence decreased from 14 to 10 per 100K</li> <li>Vancouver Coastal Health incidence remained stable from 12 to 11 per 100K</li> </ul>					
Care facility outbreaks	<u>11</u>	Testing of MSP-funded specimens decreased slightly from ~6,600 in week 24 to ~6,400 in week 25, and the percent positivity of MSP-funded specimens was stable at 11% in week 24 and 11.3% in week 25.					
Wastewater surveillance	<u>12</u>	The per capita testing rates for MSP-funded specimens between week 24 and week 25 decreased or remained stable in all age groups except in the 5-9 year-olds, where testing					
Additional resources	<u>14</u>	rates increased from 67 per 100K in week 24 to 77 per 100K in week 24. Percent positivity					
Appendix	<u>14</u>	between week 24 and week 25 decreased in those aged 0-4, 5-9, 20-39, and 60-79, while it increased in those aged 10-14, 15-19, 40-59, and 80+. Percent positivity increased the most in 10-14 year-olds, from 4.9% in week 24 to 12% in week 25.					
		Age-specific incidence rates between week 24 and week 25 decreased or remained stable in all age groups except in the 10-14 and 80+ year-olds, where incidence rates increased from 0.8 per 100K in week 24 to 3 per 100K in week 25 and from 51 per 100K in week 24 to 69 per 100K in week 25, respectively.					
		The number of people in hospital with a positive COVID-19 test decreased from 196 in week 24 to 176 in week 25. In week 25, 60+ year-olds had the highest number of people in hospital with a positive COVID-19 test, with 72 hospitalizations in 60-79 year-olds and 62 hospitalizations in 80+ year-olds.					
		The weekly number of deaths from any cause among people testing positive for COVID-19 decreased from 33 in week 24 to 28 in week 25. Similar to previous weeks, 80+ year-olds had the highest number of deaths from any cause among people testing positive for COVID-19 (17 deaths) in week 25. From week 14 to week 20 where the UCD has been reported for at least 95% of the post-transition deaths, an average of 45% of these deaths had an UCD as COVID-19.					
		In week 25, based on earliest symptom onset date (if unavailable, then outbreak declared date is used). 1 new care facility outbreak was declared in acute care.					

### BELOW ARE IMPORTANT NOTES relevant to the interpretation of cases, hospitalizations, and deaths:

- Due to changes in testing strategies in BC in 2022 focusing on targeted higher risk populations, current case counts are an underestimate of the true number of COVID-19 cases in BC. This underestimation has increased compared to the period prior to the emergence of the Omicron variant in BC.
- Hospital data include admissions for people who test positive for COVID-19 through hospital screening practices, regardless of the reason for admission. Therefore, reported hospitalizations overestimate the true number of people who are hospitalized specifically due to COVID-19 infection.
- Pre-transition (case line list) deaths include COVID-19 related deaths reported by Health Authorities up to April 1, 2022. As of April 2, 2022, post-transition (automated linkage) deaths include people who died from any cause recorded in Vital Statistics within 30 days of their first positive COVID-19 lab result date. Deaths reported after the system transition use a broader definition and will overestimate the true

number of deaths due to COVID-19 since death registration is recorded before the underlying cause of death is determined. Due to the change in data source for death data, the number of pre-transition deaths should not be compared to the number of post-transition deaths.

### BELOW ARE IMPORTANT NOTES relevant to the interpretation of data displayed in this bulletin:

- Cases include lab confirmed, lab probable, and epi-linked cases. Case definition can be found at <a href="http://www.bccdc.ca/health-professionals/clinical-resources/case-definitions/covid-19-(novel-coronavirus">http://www.bccdc.ca/health-professionals/clinical-resources/case-definitions/covid-19-(novel-coronavirus)</a>. Cases include those reported in Health Authority case line lists and positive laboratory results in the Provincial Laboratory Information Solution (PLIS) up to April 1, 2022. As of April 2, 2022, only positive laboratory results in the PLIS are included and cases who are residents from outside of BC are not included.
- Episode date is defined by date of illness onset when available. When illness onset date is unavailable, earliest laboratory date is used (collection or result date); if also unavailable, then public health case report date is used. As of April 2, 2022, episode date reflects earliest laboratory date (collection or result date) only. Analyses based on episode date may better represent the timing of epidemic evolution. Episode-based tallies for recent weeks are expected to increase as case data are more complete.
- Surveillance date is defined by lab result date, if unavailable, then public health case report date is used. As of April 2, 2022, surveillance date reflects lab result date only. The weekly tally by surveillance date includes cases with illness onset date in preceding weeks.
- Hospitalizations include those reported by Health Authorities up to April 1, 2022. As of April 2, 2022, hospitalizations are defined as individuals who test positive for COVID-19 and are hospitalized as recorded in the PHSA Provincial COVID-19 Monitoring Solution (PCMS). Hospitalizations for individuals 0-19 year-old are reported by linked hospitalization episodes from the PCMS since the beginning of the pandemic. Episode date for hospitalization is defined by admission date, if unavailable, surveillance date is used.
- Critical care admissions (HAU, ICU, and critical care surge beds) include individuals who test positive for COVID-19 and are
  in critical care admission as recorded in the PCMS. Episode date for critical care admission is defined by critical care
  admission date, if unavailable, surveillance date is used. Previously only ICU admissions were presented in this report.
  Critical care admissions comprises a broader category than ICU admissions and therefore, the number of critical care
  admissions should not be compared to number of ICU admissions from previous weeks.
- Deaths include COVID-19 related deaths reported by Health Authorities up to April 1, 2022. As of April 2, 2022, deaths are any COVID-19 lab positive cases who died from any cause recorded in Vital Statistics within 30 days of their first positive lab result date. Episode date for death is defined by death date, if unavailable, surveillance date is used.
- As of April 2, 2022, data on Health Authority outbreaks are compiled from outbreak files provided by the Health Authorities.
- Laboratory PLOVER data include Medical Service Plan (MSP) funded (e.g. clinical diagnostic tests) and non-MSP funded (e.g. screening tests) specimens.
- Per capita rates/incidences for year 2020 are based on Population Estimates 2020 (n= 5,147,772 for BC overall), for year 2021 are based on PEOPLE 2021 estimates (n= 5,194,137 for BC overall), and for year 2022 is based on PEOPLE 2021 estimates (n= 5,263,772 for BC overall).
- Data sources include Health Authority case line lists, PHSA Provincial COVID-19 Monitoring Solution (PCMS), Vital Statistics, laboratory PLOVER data, and aggregate outbreak files from Health Authorities.
- Integrated case data (including surveillance variables created using Health Authority case line lists, PCMS, and Vital Statistics) were extracted on July 04, 2022, laboratory PLOVER data on June 30, 2022, and Health Authority outbreak files on June 29, 2022.

### A. COVID-19 case counts and epidemic curves

Due to changes in testing strategies in BC in 2022 focusing on targeted higher risk populations, current case counts are an underestimate of the true number of COVID-19 cases in BC. This underestimation has increased compared to the period prior to the emergence of the Omicron variant in BC. Up to week 25, there have been 374,639 cases for a cumulative incidence of 7,117 per 100K (Table 1, Figure 1). The provincial incidence by episode date was 12 per 100K (628 cases) in week 25, which is stable compared to week 24. Incidence by episode date may increase as data become more complete in recent weeks.

As shown in **Figure 2**, incidence rates from week 24 to week 25 decreased in Northern Health (NH), Interior Health (IH) and Vancouver Coastal Health (VCH). Incidence rates were stable in Fraser Health (FH) and increased in Vancouver Island Health (VIHA) from 13 per 100K in week 24 to 15 per 100K in week 25. In week 25, the highest incidence rate was in VIHA at 15 per 100K.

Table 1. Episode-based case tallies by Health Authority, BC, Jan 15, 2020 (week 3) – Jun 25, 2022 (week 25) (N=	
374,639)	

Case tallies by episode date		Health Aut	Outside	Total				
case tames by episode date	FH	IH	VIHA	NH	VCH	Canada	TOLAT	
Week 25, case counts	256	72	132	31	137	0	628	
Cumulative case counts	165,060	66,727	36,493	30,447	75,521	391	374,639	
Week 25, cases per 100K population	13	9	15	10	11	NA	12	
Cumulative cases per 100K population	8,306	8,055	4,146	9,947	5,985	NA	7,117	

Figure 1. Episode-based epidemic curve (bars), surveillance date (line) and Health Authority (HA), BC Sept 13, 2020 (week 38) – Jun 25, 2022 (week 25) (N= 366,792)



# Figure 2. Weekly episode-based incidence rates by HA and health service delivery area (HSDA), BC Sept 13, 2020 (week 38) – Jun 25, 2022 (week 25) (N= 366,792)



### B. Test rates and percent positive

<u>COVID-19 testing guidelines</u> recommend testing for people who have COVID-19 symptoms, and are at risk of more severe disease or live/work in high-risk settings. As shown by the darker-colored bars and dotted line in <u>Figure 3</u>, the number of MSP-funded specimens decreased slightly from ~6,600 in week 24 to ~6,400 in week 25, and the percent positivity of MSP-funded specimens was stable at 11% in week 24 and 11.3% in week 25.

As shown by the dotted lines in Figure 4, the per capita testing rates for MSP-funded specimens (dotted lines in Panel A) decreased from week 24 to week 25 in all HAs except VIHA, where it was stable. In week 25, FH had the highest testing rate at 161 per 100K. The percent positivity (dotted lines in Panel B) for MSP-funded specimens decreased or remained stable from week 24 to week 25 in all HAs except VIHA, where it increased from 17.4% in week 24 to 19.2% in week 25. In week 25, percent positivity ranged from 9.1% in FH to 19.2% in VIHA.

# Figure 3. Number of specimens tested and percent SARS-CoV-2 positive, by collection week, BC Sept 13, 2020 (week 38) – Jun 25, 2022 (week 25)



Note: Invalid (n = 3787) and indeterminate (n = 20179) results have been excluded

# Figure 4. Testing rates and percent SARS-CoV-2 positive by Health Authority and collection week, BC Sept 13, 2020 (week 38) – Jun 25, 2022 (week 25)



Data source: Laboratory PLOVER data

### C. Age profile – Testing and cases

### Testing rates and percent positivity by age group

As shown by the bars in <u>Figure 5</u>, the per capita testing rates for MSP-funded specimens between week 24 and week 25 decreased or remained stable in all age groups except in the 5-9 year-olds, where testing rates increased from 67 per 100K in week 24 to 77 per 100K in week 24.

As shown by the black dots in **Figure 5**, percent positivity between week 24 and week 25 decreased in those aged 0-4, 5-9, 20-39, and 60-79, while it increased in those aged 10-14, 15-19, 40-59, and 80+. Percent positivity increased the most in 10-14 year-olds, from 4.9% in week 24 to 12% in week 25, though testing volumes were low in this age group. In week 25, percent positivity ranged from 5.9% in 15-19 year-olds to 12.3% in 80+ year-olds.

### Case distribution and weekly incidence by age group

As shown in <u>Figure 6</u>, age-specific incidence rates between week 24 and week 25 decreased or remained stable in all age groups except in the 10-14, and 80+ year-olds, where incidence rates increased from 0.8 per 100K in week 24 to 3 per 100K in week 25 and from 51 per 100K in week 24 to 69 per 100K in week 25, respectively.

Figure 5. Average weekly SARS-CoV-2 MSP testing rates and MSP percent positive by known age group, BC May 21, 2022 (week 20) – Jun 25, 2022 (week 25)



Data source: Laboratory PLOVER data





### D. Severe outcome counts and epi-curve

Hospital data include admissions for people who test positive for COVID-19 through hospital screening practices, regardless of the reason for admission. Therefore, reported hospitalizations overestimate the true number of people who are hospitalized specifically due to COVID-19 infection. The number of people in hospital with a positive COVID-19 test decreased from 196 in week 24 to 176 in week 25. In week 25, 60+ year-olds had the highest number of people in hospital with a positive COVID-19 test, with 72 hospitalizations in 60-79 year-olds and 62 hospitalizations in 80+ year-olds.

As of April 2, 2022, death data include people who test positive for COVID-19 and died from any cause (COVID-19 or non-COVID-19) within 30 days of their first positive lab result date. The weekly number of deaths from any cause among people testing positive for COVID-19 decreased from 33 in week 24 to 28 in week 25. Similar to previous weeks, 80+ year-olds had the highest number of deaths from any cause among people testing positive for COVID-19 (17 deaths) in week 25 (Table 2, Figure 8). Detailed information about outcomes by vaccination status can be accessed at <u>BCCDC COVID-19 Regional Surveillance Dashboard</u>.

Cumulatively, there have been 32 confirmed cases of <u>Multi-system Inflammatory Syndrome in children and adolescents (MIS-</u> <u>C)</u> in BC since January 1, 2020. There have been no new confirmed cases of MIS-C since the last report. The median age of all cases is 9 years old (range from 4 months old to 16 years old).

Table 2. COVID-19 severe outcomes by episode date, Health Authority of residence, BC
Jan 15, 2020 (week 3) – Jun 25, 2022 (week 25)

Course outcomes hu opicado data		Health Au	thority of r	esidence	Residing			
Severe outcomes by episode date	FH	IH	VIHA	NH	VCH	outside of Canada	Total n/N <sup>a</sup> (%)	
Week 25, hospitalizations	84	11	39	5	37	0	176	
Cumulative hospitalizations	11,267	4,144	2,296	2,048	4,791	17	24,563/374,639 (7)	
Week 25, critical care admissions <sup>b</sup>	15	5	3	3	6	0	32	
Cumulative critical care admissions <sup>b</sup>	2,379	964	399	781	1,071	4	5,598/374,639 (1)	
Week 25, deaths	12	5	5	1	5	0	28	
Cumulative deaths, pre-transition (case line list) <sup>c</sup>	1,348	367	241	330	716	0	3,002/356,565 (1)	
Cumulative deaths, post-transition (automated linkage) <sup>c</sup>	243	168	145	28	173	0	757/18,074 (4)	

a. Cases with unknown outcome are included in the denominators (i.e. assumed not to have the specified severe outcome).

b. Due to the change in data source for hospitalization data, ICU admissions are no longer available. Critical care admissions are now being provided, which comprises a broader category than ICU admissions (please see Important Notes on Page 2 for more information). Number of critical care admissions should not be compared to number of ICU admissions from previous weeks.

c. Pre-transition (case line list) deaths include COVID-19 related deaths reported by Health Authorities up to April 1, 2022. As of April 2, 2022, posttransition (automated linkage) deaths are any COVID-19 lab positive cases who died from any cause recorded in Vital Statistics within 30 days of their first positive lab result date. Deaths reported after the system transition use a broader definition and will overestimate the true number of deaths due to COVID-19 since death registration is recorded before the underlying cause of death is determined. Due to the change in data source for death data, the number of pre-transition deaths should not be compared to the number of post-transition deaths. Figure 8. Weekly COVID-19 hospital admissions (A) and deaths (B) by age groups, BC, Sept 13, 2020 (week 38) – Jun 25, 2022 (week 25)<sup>a</sup>



a. Among those with available age information only.

### E. Age profile, severe outcomes

Table 3 displays the distribution of cases and severe outcomes. In week 25, median age of hospital admissions, critical care admissions, pre-transition deaths, and post-transition deaths with underlying cause of death (UCD) as COVID-19 was 66 years, 63 years, 82 years, and 86 years, respectively.

In the past four weeks (from week 22 to week 25), there has been a weekly average of 3 deaths in those <60 years of age, 3 deaths in 60-69 year-olds, 11 deaths in 70-79 year-olds and 29 deaths in the 80+ year-olds (data not shown). The number of deaths may increase over time as data becomes more complete.

Table 3: COVID-19 cases, hospitalizations, critical care admissions, and deaths by age group, BC, Jan 15, 2020 (wee	ek 🛛
3) – Jun 25, 2022 (week 25) (N= 374,608) <sup>a</sup>	

			Critical care	<b>Pre-transition</b>	Post-transition (automated linkage) deaths <sup>c</sup>				
Age group (years)	Cases	Hospitalizations n (%)	admissions <sup>b</sup> n (%)	(case line list) deaths <sup>c</sup> n (%)	UCD as COVID-19 <sup>d</sup> n (%)	UCD as non-COVID-19 <sup>d</sup> n (%)	UCD pending <sup>d</sup> n (%)		
<10	30,536	523 (2)	65 (<1)	2 (<1)	1 (<1)	2 (<1)	0 (<1)		
10-19	35,729	339 (1)	47 (<1)	0 (<1)	0 (<1)	1 (<1)	0 (<1)		
20-29	73,062	1,324 (2)	196 (<1)	6 (<1)	0 (<1)	4 (<1)	2 (<1)		
30-39	69,890	2,262 (3)	413 (1)	31 (<1)	2 (<1)	5 (<1)	0 (<1)		
40-49	54,028	2,182 (4)	573 (1)	64 (<1)	1 (<1)	6 (<1)	1 (<1)		
50-59	43,837	3,045 (7)	1,030 (2)	166 (<1)	3 (<1)	14 (1)	6 (<1)		
60-69	30,192	4,121 (14)	1,385 (5)	353 (1)	21 (1)	34 (2)	8 (<1)		
70-79	17,477	4,740 (27)	1,265 (7)	655 (4)	50 (2)	71 (3)	39 (1)		
80-89	12,932	4,251 (33)	549 (4)	989 (10)	92 (3)	108 (3)	52 (2)		
90+	6,925	1,776 (26)	75 (1)	736 (15)	98 (5)	97 (5)	39 (2)		
Total	374,608	24,563	5,598	3,002	268	342	147		
Median age	36	66	63	82	86	82.5	83		

a. Among those with available age information only.

b. Due to the change in data source for hospitalization data, ICU admissions are no longer available. Critical care admissions are now being provided, which comprises a broader category than ICU admissions (please see Important Notes on Page 2 for more information). Number of critical care admissions should not be compared to number of ICU admissions from previous weeks.

c. Pre-transition (case line list) deaths include COVID-19 related deaths reported by Health Authorities up to April 1, 2022. As of April 2, 2022, posttransition (automated linkage) deaths are any COVID-19 lab positive cases who died from any cause recorded in Vital Statistics within 30 days of their first positive lab result date. Deaths reported after the system transition use a broader definition and will overestimate the true number of deaths due to COVID-19 since death registration is recorded before the underlying cause of death is determined. Due to the change in data source for death data, the number of pre-transition deaths should not be compared to the number of post-transition deaths.

d. Since underlying cause of death (UCD) takes approximately 8 weeks to be recorded, all-cause mortality is initially reported and then retrospective evaluations of underlying cause of death are provided here to better understand true COVID-19 mortality. UCD as COVID-19 are deaths that have been determined to be caused by COVID-19 in their Vital Stats record. UCD as non-COVID-19 are deaths that have been determined to be not attributable to COVID-19 in their Vital Stats record as deaths due to a lab positive COVID-19 test within 30 days of death. UCD pending are all post-transition deaths that do not yet have a recorded UCD.

### British Columbia (BC) C. VID-19 Situation Report

**Figure 9** displays the number of pre-transition deaths and post-transition deaths (i.e. people who test positive for COVID-19 and died from any cause within 30 days of their first positive lab result date) by underlying cause of death as recorded in Vital Statistics from week 6 to week 25 in 2022. From week 14 to week 20 where the UCD has been reported for at least 95% of the post-transition deaths, an average of 45% of these deaths had an UCD as COVID-19. Post-transition deaths with complete UCD are expected to increase over time.

# Figure 9: Pre- and post-transition deaths by underlying cause of death, BC, Feb 06, 2022 (week 6) – Jun 25, 2022 (week 25)<sup>a,b</sup>



Dotted line represents system transition date

- a. Pre-transition (case line list) deaths include COVID-19 related deaths reported by Health Authorities up to April 1, 2022. As of April 2, 2022, posttransition (automated linkage) deaths are any COVID-19 lab positive cases who died from any cause recorded in Vital Statistics within 30 days of their first positive lab result date. Deaths reported after the system transition use a broader definition and will overestimate the true number of deaths due to COVID-19 since death registration is recorded before the underlying cause of death is determined. Due to the change in data source for death data, the number of pre-transition deaths should not be compared to the number of post-transition deaths.
- b. Since underlying cause of death (UCD) takes approximately 8 weeks to be recorded, all-cause mortality is initially reported and then retrospective evaluations of underlying cause of death are provided here to better understand true COVID-19 mortality. UCD as COVID-19 are deaths that have been determined to be caused by COVID-19 in their Vital Stats record. UCD as non-COVID-19 are deaths that have been determined to be not attributable to COVID-19 in their Vital Stats record as deaths due to a lab positive COVID-19 test within 30 days of death. UCD pending are all post-transition deaths that do not yet have a recorded UCD.

### F. Care facility outbreaks

As shown in <u>Table 4</u> and <u>Figure 10</u>, 676 care facility (acute care and long-term care settings) outbreaks were reported in total in BC to the end of week 25. In week 25, based on earliest symptom onset date (if unavailable, then outbreak declared date is used), 1 new care facility outbreak was declared in acute care. In the past four weeks (from week 22 to week 25), there has been a weekly average of 1 care facility outbreak.

## Table 4. COVID-19 care facility<sup>a</sup> outbreaks by earliest case onset<sup>b,c</sup>, associated cases and deaths by episode date, BC Jan 15, 2020 (week 3) – Jun 25, 2022 (week 25) (N=676)<sup>d,e</sup>

Care facility outbreaks and	Outbreaks		Cases		Deaths		
cases by episode date		Residents	Staff/other	Total	Residents	Staff/other	Total
Week 25, Care Facility Outbreaks	1	16	0	16	0	0	0
Cumulative, Care Facility Outbreaks	676	9,571	3,817	13,388	1,453	0	1,453

# Figure 10. COVID-19 care facility <sup>a</sup>, outbreaks by earliest case onset<sup>b,c</sup>, facility type (A) and Health Authority (B), BC Sept 13, 2020 (week 38) – Jun 25, 2022 (week 25) (N=608)<sup>d,e</sup>



Earliest onset date by epidemiological week

- a. Case and death counts include PCR positive cases only for outbreaks in NHA and VIHA. Vancouver Coastal Health, Fraser Health Authority, and Interior Health Authority outbreaks may also include those diagnosed by rapid antigen tests or considered as suspect reinfection.
- b. Earliest dates of onset of outbreak cases are subject to change as investigations and data are updated. If unavailable, outbreak declared date is used.
  c. New outbreaks reported since the last report with an earliest case onset date (if unavailable, outbreak declared date is used) prior to the current
- reporting week will be included in the cumulative care facility outbreak total.
- d. Cases with unknown role are included in the case count for Staff/other.
- e. Data might be incomplete or vary from what was reported previously due to updates by Health Authorities.

### **G.** Wastewater surveillance

The BCCDC and Metro Vancouver measure SARS-CoV-2 in wastewater at five wastewater treatment plants (treating wastewater from 50% of BC's population). To account for changing wastewater volume due to rainfall or snowmelt, SARS-CoV-2 concentrations are normalized to wastewater flow. Normalized SARS-CoV-2 wastewater levels (measured as viral copies per day) are shown alongside incident COVID-19 cases in each wastewater catchment area in <u>Figure 10</u> and <u>Figure 11</u>. The BCCDC's test results are obtained from the liquid fraction of the wastewater sample. Other organizations, such as the National Microbiology Laboratory, test from the solid fraction of wastewater and therefore, their results are not directly comparable.

Key messages with results through to July 2<sup>nd</sup>, 2022:

- Viral loads at Iona Island have increased by 29% over the past 2 weeks.
- Viral loads at Lions Gate have increased by 115% in the past week.
- Viral loads at Lulu Island decreased by 11% in the past week.
- Viral loads at Annacis Island have increased by 35% over the past 3 weeks.
- Viral loads at Northwest Langley have increased by 251% over the past 3 weeks.



### Figure 11. Wastewater surveillance, FH

# British Columbia (BC) C VID-19 Situation Report

### Figure 12. Wastewater surveillance, VCH



### **H. Additional resources**

For maps and geographical distribution of cases and vaccinations, visit the BCCDC COVID-19 Regional Surveillance Dashboard here: <u>http://www.bccdc.ca/health-professionals/data-reports/covid-19-surveillance-dashboard</u>

Variant of concern (VOC) findings are available weekly here: <u>http://www.bccdc.ca/health-info/diseases-conditions/covid-</u> <u>19/data#variants</u>

For local, national, and global comparisons of BC to other jurisdictions on key epidemiological metrics, visit the BCCDC COVID-19 Epidemiology App here: <u>https://bccdc.shinyapps.io/covid19 global epi app/</u>

### I. Appendix

<u>Vaccination phases</u> defined by vaccine eligibility of target populations in BC

### Vaccination Phase 1 (December 2020 – February 2021)

Target populations include residents, staff and essential visitors to long-term care settings; individuals assessed and awaiting a long-term care placement; health care workers providing care for COVID-19 patients; and remote and isolated Indigenous communities.

### Vaccination Phase 2 (February 2021 – April 2021)

Target populations include seniors, age  $\geq$ 80; Indigenous peoples age  $\geq$ 65 and Indigenous Elders; Indigenous communities; hospital staff, community general practitioners and medical specialists; vulnerable populations in select congregate settings; and staff in community home support and nursing services for seniors.

### Vaccination Phase 3 (April 2021 – May 2021)

Target populations include people aged 60-79 years, Indigenous peoples aged 18-64 and people aged 16-74 who are clinically extremely vulnerable.

### Vaccination Phase 4 (May 2021 – November 2021)

Target populations include everyone 12+ years. In September, third dose is available for people who are clinically extremely vulnerable.

### Vaccination Phase 5 (November 2021 – February 2022)

Target populations include everyone 5+. Children aged 5-11 are eligible at the end of November. Everyone 18 and older will be invited to get a booster dose within 6-8 months of their second dose.

### Vaccination Phase 6 (February 2022 – April 2022)

Target populations include everyone 5+. Everyone 12 and older will be invited to get a booster dose within 6-8 months of their second dose.

### Vaccination Phase 7 (April 2022 – Present)

Target populations include everyone 5+. Everyone 12 and older will be invited to get a booster dose within 6-8 months of their second dose. People in long-term care, assisted living, seniors and Indigenous people can get a second booster 6 months after the date of the first booster.